Great Lakes Advisors, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Great Lakes Advisors, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$143.31 - $247.0 $186,159 - $320,853	1,299 New	1,299 $315,000
Q4 2023 Feb 08, 2024	SELL	$151.41 - $196.57 $5,904 - $7,666	-39 Reduced 2.7%	1,406 $269,000
Q3 2023 Nov 07, 2023	SELL	$170.77 - $211.65 $12,466 - $15,450	-73 Reduced 4.81%	1,445 $255,000
Q2 2023 Aug 10, 2023	BUY	$185.01 - $212.05 $280,845 - $321,891	1,518 New	1,518 $288,000
Q2 2021 Aug 11, 2021	SELL	$128.63 - $176.89 $844,455 - $1.16 Million	-6,565 Closed	0 $0
Q1 2021 May 03, 2021	BUY	$126.83 - $175.69 $32,468 - $44,976	256 Added 4.06%	6,565 $927,000
Q4 2020 Feb 09, 2021	BUY	$122.97 - $147.0 $122 - $147	1 Added 0.02%	6,309 $820,000
Q3 2020 Nov 04, 2020	SELL	$121.19 - $165.49 $177,179 - $241,946	-1,462 Reduced 18.82%	6,308 $918,000
Q2 2020 Aug 07, 2020	SELL	$104.21 - $156.44 $8,753 - $13,140	-84 Reduced 1.07%	7,770 $1.15 Million
Q1 2020 May 08, 2020	BUY	$93.12 - $133.99 $731,364 - $1.05 Million	7,854 New	7,854 $855,000
Q4 2019 Feb 07, 2020	SELL	$74.51 - $124.23 $11.2 Million - $18.7 Million	-150,601 Closed	0 $0
Q3 2019 Nov 06, 2019	BUY	$70.9 - $87.82 $10.7 Million - $13.2 Million	150,601 New	150,601 $12.1 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Great Lakes Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Great Lakes Advisors, LLC with notifications on news.